Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis
Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis
About this item
Full title
Author / Creator
Publisher
Waltham, MA: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
Waltham, MA: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
In this 12-week, phase 2 trial, an anti–interleukin-17–receptor antibody was effective in treating moderate-to-severe psoriasis. Adverse events included neutropenia. Larger trials of longer duration are needed to assess the risk of infections.
Psoriasis is a chronic T-cell–mediated autoimmune disease
1
that affects 2 to 3% of the U.S. popu...
Alternative Titles
Full title
Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_963488448
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_963488448
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1109017
